Log In
Print
BCIQ
Print
Print this Print this
 

KD020

  Manage Alerts
Collapse Summary General Information
Company Kadmon Corp. LLC
DescriptionReversible tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR), EGFR2 (HER2; ErbB2; neu), VEGF receptor 2 and 3, and Src kinase
Molecular Target Epidermal growth factor receptor (EGFR) ; Epidermal growth factor receptor 2 (EGFR2) (HER2) (ErbB2) (neu)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I/II
Standard IndicationPolycystic kidney disease (PKD)
Indication DetailsTreat autosomal dominant polycystic kidney disease (ADPKD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today